Perseis Therapeutics

Therapeutic products that specifically target molecules involved in cancer progression and spread — known as molecularly targeted cancer therapies — are increasingly recognised as the future of cancer therapy. For breast cancer, these include Herceptin® and Tamoxifen, which target the HER2 and estrogen receptors, respectively. However, many breast cancers neither express the estrogen receptor nor are HER2 positive and are, therefore, not responsive to the therapies that target them. Perseis’s cancer program targets the Trefoil Factors (TFF-1 and TFF-3) and Growth Hormone which have been found to play a significant role in the growth and spread of breast cancer as well as response to treatment and offer promising targets for development of therapies for cancers which are not responsive to currently available drugs. In vitro and in vivo studies have demonstrated strongly positive effects of antibodies directed against these molecules in breast and other cancers.